FindTrial
Sign In

recombinant MAGE-3.1 antigen

BIOLOGICAL4 trials

Sponsors

University of Chicago, Baylor Health Care System, University of Southern California, National Cancer Institute (NCI)

Conditions

Ciliary Body and Choroid Melanoma, Medium/Large SizeCiliary Body and Choroid Melanoma, Small SizeExtraocular Extension MelanomaIris MelanomaMelanoma (Skin)Metastatic Intraocular MelanomaMucosal MelanomaRecurrent Intraocular Melanoma

Phase 1

Vaccine Therapy and Interleukin-12 in Treating Patients With Metastatic Melanoma
CompletedNCT00002952
University of ChicagoMelanoma (Skin)
Start: 1997-01-31End: 2002-11-30Updated: 2013-09-05
Vaccine Therapy in Treating Patients With Metastatic Melanoma
CompletedNCT00003792
Baylor Health Care SystemMelanoma (Skin)
Start: 1999-04-30End: 2006-10-31Updated: 2013-06-26

Phase 2

Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma
CompletedNCT00085189
University of Southern CaliforniaCiliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size, Extraocular Extension Melanoma +14
Start: 2004-05-31End: 2007-09-30Updated: 2014-05-22
Vaccine Therapy With or Without Recombinant Interleukin-12 Followed by Daclizumab in Treating Patients With Metastatic Melanoma
TerminatedNCT01307618
National Cancer Institute (NCI)Recurrent Melanoma, Stage IV Skin Melanoma
Start: 2011-02-28End: 2015-02-28Updated: 2016-10-24